The EHE Foundations have been actively supporting Dr Rubin’s small but dedicated EHE research team at the Cleveland Clinic in the USA, and were excited to receive his latest update in April. Dr Rubin provided an overall update to the EHE community but was particularly pleased to be able to report important progress in two key areas: (i) development of an EHE mouse model; and (ii) identification of proteins resulting from the gene mutation that causes EHE, and that will be key to therapeutic drug screening.
In addition, Dr Rubin was able to confirm that Clinical trial NCI Protocol # 10015 / SARC033, co-sponsored by the NCI and SARC and entitled “A Non-Randomized, Open-Label Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Haemangioendothelioma”, would start on 1st May. Essentially, the trial will examine the effect of MEK (MAP kinase) inhibition on EHE progression. Funding for biopsies in this study will be provided by the EHE foundations. The Principal Investigator of the clinical trial is Dr Scott Schuetze (University of Michigan), who has done a wonderful job bringing the trial to reality.
Kate Hooper, Trustee of the EHERCC, said “we are delighted to see this progress on several fronts. So many people work hard to raise funds for EHE research, not only in the UK, but worldwide, so we are always pleased to be able to provide them with feedback on what that research is leading too.” The EHE foundations look forward to providing further important updates later in the year.